Trastuzumab deruxtecan belongs to a group of antineoplastic drugs known as antibody-drug conjugates (ADCs). This type of ...

AstraZeneca and Daiichi Sankyo's anti-HER2 drug Enhertu has been shown to provide a benefit in a phase 3 trial in early-stage breast cancer for the first time, setting up regulatory filings.

AstraZeneca and Daiichi Sankyo are preparing regulatory filings that could make their HER2-directed antibody-drug conjugate (ADC) Enhertu an option for previously untreated breast cancer for the ...

During a Community Case Forum event, Antoinette R. Tan, MD, MHS, discussed the DESTINY-Breast04 and DESTINY-Breast06 trials ...

Roche’s Herceptin and Perjeta duo is already part of a well-established standard of care in early-stage HER2-positive breast ...

Camizestrant with a CDK 4/6 inhibitor had a statistically significant and clinically meaningful improvement in PFS in HR+/HER2– advanced breast cancer. Dr. Debu Tripathy breaks down the FDA approval ...

T-DXd monotherapy and T-DXd plus pertuzumab continue to show robust efficacy in HER2-positive metastatic breast cancer.

England’s drug approval body has resisted pressure from pharmaceutical companies to loosen its process for recommending drugs ...

Enliven Therapeutics has decided against taking its phase 1-stage solid tumor drug into further development next year in ...